Intracranial ependymomas are a common pediatric brain cancer. Advances in molecular profiling over the past decade have led to the identification of nine distinct molecular subgroups of ependymomas across three anatomical areas of the central nervous system. Radiation therapy, though effective at killing tumor cells, can cause major toxicities for patients and lead to the potential development of systemic resistance to subsequent therapies. It is still important to determine which molecular subgroups of ependymomas may benefit from post-radiation chemotherapy and which patients are resistant to post-radiation treatment. The central hypothesis of this research is that molecular subgroups of ependymomas acquire identifiable mutations following ionizing radiation exposure. Researchers believe this in turn contributes to the development of resistance to treatment. Researchers expect that the completion of this project will help elucidate the difference in response to radiation and chemotherapy across molecular ependymoma subgroups, informing future therapeutics. This project will involve the study of cell lines from each of the subgroups most common in children, specifically PF-EPN-A, STEPN- RELA, ST-EPN-YAP1. Ependymoma tumors are rare in children and ependymoma cell lines are difficult to establish, making the Children’s Brain Tumor Network provision of preclinical models particularly important to this work.
What are the goals of this project?
Researchers will analyze cell lines from many subgroups of ependymoma in an effort to understand why some subgroups are more resistant to treatment than others.
What is the impact of this project?
Researchers expect that the completion of this project will help in understanding the difference in response to radiation and chemotherapy across molecular ependymoma subgroups, informing future therapeutics.
Why is the CBTN request important to this project?
Ependymoma cell lines are hard to establish, making the Children’s Brain Tumor Network’s provision of high quality cell lines integral to this work.
The Children's Brain Tumor Network is contributing to this project by providing preclinical models.
Jeffrey Greenfield, MD, PhD
Dr. Greenfield’s directs multiple research projects pertaining to pediatric brain tumors, in particular, basic research examining the brain tumor microenvironment, tumor immunology, and precision medicine. This research has been externally funded and widely published and he has received national awa
Weill Cornell Medicine
Nadia Dahmane, PhD
Dr. Dahmane’s current research focuses a group of proteins called transcription factors that regulate how different genes are expressed during both brain development and brain cancer progression. Her laboratory has identified a critical novel transcription factor protein (called RP58) that is indisp
Weill Cornell Medicine
Weill Cornell MedicineJoined on
The Weill Cornell Medicine Pediatric Brain and Spine Center, located on the Upper East Side campus of New York-Presbyterian/Weill Cornell Medical Center, is nationally recognized for its leadership in the treatment of disorders of the central nervous system in children, particularly brain and spinal
Ependymomas arise from ependymal cells that line the ventricles and passageways in the brain and the center of the spinal cord. Ependymal cells produce cerebrospinal fluid (CSF). These tumors are classified as supratentorial or infratentorial. In children, most ependymomas are infratentorial tumors